T-Curx received Swissmedic clinical trial approval for its nonviral, Siglec-6-targeted CAR T program TCX-001, clearing a first-in-human phase I study in Switzerland. The company said it plans to submit to the EMA to expand the trial into Germany. The trial will enroll adults with relapsed or refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including patients not eligible for stem cell transplantation. The approval marks a regulatory step for a platform positioned around a nonviral lead CAR T approach.